Contract Deobligations Alert — March 31, 2026

Raytheon, TRAX, Lockheed, and Caltech secure 67% of period value in low/no competition deals for instruments, logistics, and MAVEN/DSOC projects extending to 2029.

HII, Sevenson, and Hensel Phelps win cost-plus/firm-fixed deals for GSA/DoD/DOI services through 2032, with $180M+ fresh awards signaling remediation and construction momentum.

$256M firm-fixed botulism antitoxin obligation (73% outlayed) provides steady pharma flow despite foreign subsidiary structure.

Extended periods (avg. 10+ years to 2032) with low outlays (e.g., Raytheon 26% disbursed, Lockheed 14%) expose to cost overruns, audits, and performance-tied award fees.

Remaining $1.3B+ unobligated (42% of total) hinges on NASA/DoD/HHS budgets; contracts near end (TRAX 2024) risk non-renewal.

Foreign-owned Emergent Canada and cost-plus structures invite sourcing scrutiny or disallowances.

$940M+ in unobligated options/base+options excess across portfolio, led by HII ($509M) and Raytheon ($32M).

Follow-on potential from reissued (TRAX) and FFRDC (Caltech) structures in NASA space R&D.

DoD environmental remediation ($180M Sevenson) and HHS biodefense ($256M Emergent) diversify beyond space.

67% of value ($2.06B) in 4 long-term contracts for vehicles, instruments, and logistics, favoring non-competed primes.

7/8 contracts use cost-plus/award-fee, shielding margins but tying to evaluations amid low outlays.

{"entity"=>"RTX (Raytheon)", "reason"=>"Largest single award ($1.22B, 40% of total) with $939M remaining and 2029 horizon.", "trigger"=>"Q2 outlay acceleration or VIRS follow-on award"}

{"entity"=>"TRAX International", "reason"=>"Nearing 2024 end ($118M remaining); reissued history signals renewal path.", "trigger"=>"extension beyond Oct 2024 or new GSFC logistics RFP"}

{"entity"=>"HII Mission Technologies", "reason"=>"Highest options upside ($509M) in GSA engineering, post-2025 renewal likely.", "trigger"=>"task order expansions or FY2026 GSA budget"}